RxDoctor Payments Data

Susan Zweizig, MD

Gynecologic Oncology · Worcester, MANPI 1992786925

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Tesaro, Inc. accounts for 85.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for gynecologic oncology clinicians in MA, where the typical reported total is $400.

$168in general payments, 2019–2025

Across 4 payments — averaging $42.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tesaro, Inc.$144
  • Intuitive Surgical$24
$671,456in research payments, 2019–2025

Across 66 payments — averaging $10,174 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$476K
  • GSK$111K
  • Tesaro, Inc.$65K
  • AbbVie$19K

What the payments were for

  • Food & beverage$168100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Tesaro, Inc.2$144
Intuitive Surgical2$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$168 in reported general payments places this provider in the 35th percentile of 32 gynecologic oncology providers in Massachusetts.

See all gynecologic oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$57,397
Medicare patients
150
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate17$401,010
LynparzaOlaparib11$166,674
EliquisApixaban19$13,404
XareltoRivaroxaban16$10,656
Megestrol Acetate33$1,936
Prochlorperazine Maleate38$1,150
Ondansetron Hcl41$475
Dexamethasone48$400
Fluconazole14$58

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →